FDA fast track covers ART6043 plus olaparib in PARP inhibitor–naïve gBRCAm, HER2-negative locally advanced/metastatic breast ...

Primary CNS lymphoma is a rare and aggressive cancer with no FDA-approved treatments specific to the disease. While some ...

Cancer-related fatigue may persist despite improved sleep or treated depression, underscoring it as a distinct and complex symptom.

Cancer-related fatigue is distinct from sleep problems, even though the two symptoms often feel closely connected, according to Susanna M. Zick, professor in the Department of Fam ...

In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma.

Dr. William Audeh discusses how genomic subtyping can close the 38% mortality gap for Black women by identifying aggressive ...

The FDA application is supported by data from the Phase 3 evERA Breast Cancer study. The trial results showed that the combination of giredestrant and Afinitor reduced the risk of disease progression ...

The U.S. Food and Drug Administration (FDA) has cleared an investigational new drug application from FluoGuide A/S in Copenhagen, Denmark, allowing the company to move forward in the U.S. with a ...

Sovereign status of Native Nations necessitates nation-to-nation healthcare relationships, including treaty-informed ...

Stage 1 mesothelioma is localized. The cancer is confined to one side of the chest lining or one area of the abdomen and has ...

A diagnosis of Kaposi sarcoma is a significant life event, but it is a manageable condition. Because KS is so closely linked ...

A study led by Dr. J. William Harbour of UT Southwestern Medical Center marks a shift in how doctors predict the spread of uveal melanoma.